KalVista Pharmaceuticals (KALV) Cash from Investing Activities (QoQ) (2014 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 738.85% |
| Oct 31, 2024 | 30.98% |
| Jul 31, 2024 | 129.45% |
| Apr 30, 2024 | -1,782.81% |
| Jan 31, 2024 | -123.47% |
| Oct 31, 2023 | 45.60% |
| Jul 31, 2023 | 415.83% |
| Apr 30, 2023 | -146.72% |
| Jan 31, 2023 | -112.52% |
| Oct 31, 2022 | -33.10% |
| Jul 31, 2022 | 141.63% |
| Apr 30, 2022 | -3.63% |
| Jan 31, 2022 | -26.87% |
| Oct 31, 2021 | 18.56% |
| Jul 31, 2021 | 108.94% |
| Apr 30, 2021 | -2,497.16% |
| Jan 31, 2021 | 9.01% |
| Oct 31, 2020 | 15.56% |
| Jul 31, 2020 | -45.02% |
| Apr 30, 2020 | 2.63% |
| Jan 31, 2020 | 745.31% |
| Oct 31, 2019 | 1.05% |
| Jul 31, 2019 | 89.11% |
| Apr 30, 2019 | 74.27% |
| Jan 31, 2019 | -24,600.90% |
| Oct 31, 2018 | 60.88% |
| Jul 31, 2018 | 47.88% |
| Apr 30, 2018 | -495.60% |
| Jan 31, 2018 | -256.86% |
| Oct 31, 2017 | 53.64% |
| Jul 31, 2017 | -1,471.43% |
| Apr 30, 2017 | -100.02% |
| Jan 31, 2017 | 189,727.78% |
| Oct 31, 2016 | 58.14% |
| Mar 31, 2016 | 83.18% |
| Dec 31, 2015 | -5,109.52% |
| Sep 30, 2015 | 73.42% |
| Jun 30, 2015 | 56.11% |
| Sep 30, 2014 | 90.67% |
| Jun 30, 2014 | -7,400.00% |